The World Bank

The control of human onchocerciasis (river blindness) is one of the most successful global partnerships ever supported by the World Bank. Mectizan mass treatments have greatly contributed to this success and have shaped the strategies of the programmes in which the World Bank has been involved - the...

Full description

Bibliographic Details
Main Author:	Bangoura, O.
Format:	Journal Article
Language:	EN
Published:	2012
Subjects:	Africa/epidemiology Animals Delivery of Health Care Developing Countries Filaricides Humans Ivermectin Onchocerciasis economics
Online Access:	http://hdl.handle.net/10986/5056

id	okr-10986-5056
recordtype	oai_dc
spelling	okr-10986-50562021-04-23T14:02:20Z The World Bank Bangoura, O. Africa/epidemiology Animals Delivery of Health Care Developing Countries Filaricides Humans Ivermectin Onchocerciasis Onchocerciasis economics The control of human onchocerciasis (river blindness) is one of the most successful global partnerships ever supported by the World Bank. Mectizan mass treatments have greatly contributed to this success and have shaped the strategies of the programmes in which the World Bank has been involved - the Onchocerciasis Control Programme (OCP), which covered onchocerciasis control in West Africa until 2002, and the African Programme for Onchocerciasis Control (APOC), which is currently working in 30 countries, to protect millions of people from onchocerciasis. Through the strategy of community-directed treatment with ivermectin (CDTI), onchocerciasis control in Africa was transformed from a technologically-driven and vertical health initiative to a community-directed process of treatment and empowerment. Together, CDTI and the donation of Mectizan also reduced costs, producing one of the most effective and affordable disease-control schemes ever seen, and the CDTI strategy is now being applied to other disease-control initiatives. The onchocerciasis programmes have also been exemplary in shaping partnerships with communities, countries, the World Health Organization, governments, non-governmental development organizations, and the private sector. The Bank's involvement in onchocerciasis control has helped mobilize funds, giving confidence to other donors. More than U. S.$800 million was raised for both the OCP and APOC (excluding the initial costs of Mectizan). With these funds and the commitment of the partners involved, high coverages have been achieved in the Mectizan distributions. The Bank is confident that, during the years to come, the partners will continue their success, and that the APOC will achieve its goals by the target date for its closure, in 2015. 2012-03-30T07:31:03Z 2012-03-30T07:31:03Z 2008 Journal Article Ann Trop Med Parasitol 0003-4983 (Print) 0003-4983 (Linking) http://hdl.handle.net/10986/5056 EN http://creativecommons.org/licenses/by-nc-nd/3.0/igo World Bank Journal Article
repository_type	Digital Repository
institution_category	Foreign Institution
institution	Digital Repositories
building	World Bank Open Knowledge Repository
collection	World Bank
language	EN
topic	Africa/epidemiology Animals Delivery of Health Care Developing Countries Filaricides Humans Ivermectin Onchocerciasis Onchocerciasis economics
spellingShingle	Africa/epidemiology Animals Delivery of Health Care Developing Countries Filaricides Humans Ivermectin Onchocerciasis Onchocerciasis economics Bangoura, O. The World Bank
relation	http://creativecommons.org/licenses/by-nc-nd/3.0/igo
description	The control of human onchocerciasis (river blindness) is one of the most successful global partnerships ever supported by the World Bank. Mectizan mass treatments have greatly contributed to this success and have shaped the strategies of the programmes in which the World Bank has been involved - the Onchocerciasis Control Programme (OCP), which covered onchocerciasis control in West Africa until 2002, and the African Programme for Onchocerciasis Control (APOC), which is currently working in 30 countries, to protect millions of people from onchocerciasis. Through the strategy of community-directed treatment with ivermectin (CDTI), onchocerciasis control in Africa was transformed from a technologically-driven and vertical health initiative to a community-directed process of treatment and empowerment. Together, CDTI and the donation of Mectizan also reduced costs, producing one of the most effective and affordable disease-control schemes ever seen, and the CDTI strategy is now being applied to other disease-control initiatives. The onchocerciasis programmes have also been exemplary in shaping partnerships with communities, countries, the World Health Organization, governments, non-governmental development organizations, and the private sector. The Bank's involvement in onchocerciasis control has helped mobilize funds, giving confidence to other donors. More than U. S.$800 million was raised for both the OCP and APOC (excluding the initial costs of Mectizan). With these funds and the commitment of the partners involved, high coverages have been achieved in the Mectizan distributions. The Bank is confident that, during the years to come, the partners will continue their success, and that the APOC will achieve its goals by the target date for its closure, in 2015.
format	Journal Article
author	Bangoura, O.
author_facet	Bangoura, O.
author_sort	Bangoura, O.
title	The World Bank
title_short	The World Bank
title_full	The World Bank
title_fullStr	The World Bank
title_full_unstemmed	The World Bank
title_sort	world bank
publishDate	2012
url	http://hdl.handle.net/10986/5056
_version_	1764393767642595328

The World Bank

Similar Items